An observational study in Insulin Resistance Syndrome, Cardio Vascular Disease and Prevalence, sponsored by Comune di Napoli. Completed at 1 site in Italy. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Comune di Napoli · Observational
This is an observational retrospective study to verify the prevalence of insulin resistance (IR) in the municipality of Naples and ita association with cardiovascular diseases.
Primary outcome measure 1: The prevalence of IR. Primary outcome measure 2: The prevalence of cardiovascular diseases in subjects with IRnand in subjects without IR.
The data for analysis will be derived from the database of COMEGEN, a cooperative of general practitioners (ASL Napoli 1 Centro)who follow about 200,000 individuals of the ten districts of the municipality of Naples. As surrogate index of IR will be used the TyG with the cutoff ≥8.5. Aldo the prevalence of cardiovascular diseases in the two groups will be derivedby the registered cardiovascular diseases in the database.
2,116 studies on the registry are indexed under Metabolic Syndrome; 347 are open to participants now.
This study's enrollment of 123,752 is above the median of 197 across 496 observational studies indexed under Metabolic Syndrome.
Browse Metabolic Syndrome studies →This is the only study on the registry with Comune di Napoli as lead sponsor.
Counted across the registry records on this site, refreshed daily.
All the subjects registered in the database of COMEGEN aged between 18 and 60 without a diagnosis of diabetes
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
There is no intervention
Prevalence of insulin resistance
Time frame: 30 days
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.